AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8883650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast FLAIR imaging
Number of subjects: 45
Study 8883650 — intervention group
Group type: COMPARATOR
Intervention: T1-, proton density-, and T2-weighted images
Number of subjects: 45
Study 1565752 — intervention group
Group type: EXPERIMENTAL
Intervention: NEG emotion
Number of subjects: 20
Study 1565752 — intervention group
Group type: EXPERIMENTAL
Intervention: POS emotion
Number of subjects: 20
Study 1565752 — intervention group
Group type: COMPARATOR
Intervention: Speech alone
Number of subjects: 20
Study 30803168 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal preparation with polyethylene glycol
Number of subjects: 120
Study 30803168 — intervention group
Group type: COMPARATOR
Intervention: Non intestinal preparation
Number of subjects: 120
Study 28686338 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT applied early (within 28 days post-stroke)
Number of subjects: 47
Study 28686338 — intervention group
Group type: COMPARATOR
Intervention: CIMT applied late (6 months post-stroke)
Number of subjects: 47
Study 27103154 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored intervention (game with tailored feedback on alcohol awareness)
Number of subjects: 0
Study 27103154 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 0
Study 25491714 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief educational and counseling intervention
Number of subjects: 171
Study 25491714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 171
Study 25491714 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for chlamydia and gonorrhea
Number of subjects: 171
Study 21939591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy for psychosis (CBT-P)
Number of subjects: 0
Study 21939591 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 19584345 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose PCV-7 schedule (2 and 4 months)
Number of subjects: 1003
Study 19584345 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 + 1-dose PCV-7 schedule (2, 4, and 11 months)
Number of subjects: 1003
Study 19584345 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dosage)
Number of subjects: 1003
Study 19584345 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 + 1-dose PCV-7 schedule
Number of subjects: 1003
Study 19584345 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose PCV-7 schedule
Number of subjects: 1003
Study 18240275 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg antofloxacin hydrochloride
Number of subjects: 12
Study 18240275 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg antofloxacin hydrochloride
Number of subjects: 12
Study 18240275 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg antofloxacin hydrochloride
Number of subjects: 12
Study 16015377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 2501
Study 16015377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2501
Study 14562857 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine-containing regimens
Number of subjects: 96
Study 14562857 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple drug regimens containing Nevirapine
Number of subjects: 96
Study 14562857 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens containing didanosine and stavudine plus indinavir or Nevirapine
Number of subjects: 96
Study 10474140 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8899318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ukrain treatment in preoperative phase
Number of subjects: 18
Study 8899318 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Ukrain treatment)
Number of subjects: 18
Study 1844999 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactate (PL: 80% polylactate, 20% sodium lactate, in 7% solution with water)
Number of subjects: 5
Study 1844999 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymer (GP: multidextrin in 7% solution with water)
Number of subjects: 5
Study 1844999 — intervention group
Group type: COMPARATOR
Intervention: Control (C: water sweetened with aspartame)
Number of subjects: 5
Study 6097377 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg p.o.) in acute studies
Number of subjects: 23
Study 6097377 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril titrated from 5 mg to 20 mg twice a day in chronic studies
Number of subjects: 23
Study 30665383 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29898055 — intervention group
Group type: EXPERIMENTAL
Intervention: GI - enamel microabrasion
Number of subjects: 70
Study 29898055 — intervention group
Group type: EXPERIMENTAL
Intervention: GII - microabrasion associated with at-home bleaching
Number of subjects: 70
Study 29898055 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 70
Study 29898055 — intervention group
Group type: COMPARATOR
Intervention: Whole sample
Number of subjects: 70
Study 27127325 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + AZM tablets
Number of subjects: 40
Study 27127325 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 40
Study 27127325 — intervention group
Group type: EXPERIMENTAL
Intervention: AZM patch monotherapy
Number of subjects: 40
Study 27127325 — intervention group
Group type: EXPERIMENTAL
Intervention: AZM tablet as monotherapy
Number of subjects: 40
Study 27127325 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + AZM patch
Number of subjects: 40
Study 27127325 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + AZM tablet
Number of subjects: 40
Study 25444588 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic field stimulation (tSMS) for 10 and 15 min
Number of subjects: 10
Study 25444588 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study 25444588 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic field stimulation (tSMS) applied while recording SEPs every 3 min for 15 min
Number of subjects: 10
Study 21956486 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided street soccer (2.2 ± 0.7 sessions/week)
Number of subjects: 32
Study 21956486 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (0.5 ± 0.2 sessions/week)
Number of subjects: 32
Study 19161955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower Therapy
Number of subjects: 0
Study 17313701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of pancreatic polypeptide (PP) at 5 pmol/kg per min
Number of subjects: 14
Study 17313701 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 14
Study 17313701 — intervention group
Group type: EXPERIMENTAL
Intervention: PP infusion
Number of subjects: 14
Study 15356657 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose etoposide (50 mg/m² per day) administered orally as a single agent for 7 days
Number of subjects: 45
Study 15356657 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose etoposide (50 mg/m² per day) administered orally
Number of subjects: 45
Study 11254520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 49) with a respiratory therapist‐driven weaning protocol including daily screens and spontaneous breathing trials (SBT) for 2 hours.
Number of subjects: 100
Study 11254520 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 51) with standard care.
Number of subjects: 100
Study 11254520 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes for both groups.
Number of subjects: 100
Study 11254520 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS score as a predictor of extubation success.
Number of subjects: 100
Study 9637578 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive health education groups (N=34)
Number of subjects: 71
Study 9637578 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group (N=37)
Number of subjects: 71
Study 8207324 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacrisomes
Number of subjects: 0
Study 8207324 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein-hydrated Collasomes in methylcellulose vehicle
Number of subjects: 0
Study 8207324 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 2521471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1.5 gm a day for 3 months
Number of subjects: 12
Study 2521471 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 women)
Number of subjects: 12
Study 1153148 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA (Depo-Provera, Upjohn) 150 mg IM monthly
Number of subjects: 57
Study 1153148 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline 1.5 ml IM monthly (Control)
Number of subjects: 57
Study 31837640 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (30 mg/d)
Number of subjects: 140
Study 31837640 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU/d)
Number of subjects: 140
Study 31837640 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (30 mg/d) + Vitamin D (2000 IU/d)
Number of subjects: 140
Study 31837640 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Vitamin D placebo + Zinc placebo)
Number of subjects: 140
Study 30232789 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH
Number of subjects: 33
Study 30232789 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 33
Study 28494777 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy plus oseltamivir
Number of subjects: 127
Study 28494777 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial therapy alone (control group)
Number of subjects: 127
Study 25602059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐atrial lateral tunnel (ILT)
Number of subjects: 115
Study 25602059 — intervention group
Group type: COMPARATOR
Intervention: Extracardiac conduit (ECC)
Number of subjects: 115
Study 25602059 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter recordings
Number of subjects: 115
Study 23781882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 40
Study 23781882 — intervention group
Group type: COMPARATOR
Intervention: Control (group A)
Number of subjects: 40
Study 21226960 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help coping advice emails (twice weekly for six weeks)
Number of subjects: 0
Study 21226960 — intervention group
Group type: COMPARATOR
Intervention: General information about depression emails (twice weekly for six weeks)
Number of subjects: 0
Study 18157642 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral collagen injection midurethrally
Number of subjects: 30
Study 18157642 — intervention group
Group type: COMPARATOR
Intervention: Transurethral collagen injection at the bladder neck
Number of subjects: 30
Study 16827020 — intervention group
Group type: EXPERIMENTAL
Intervention: Base with a polyacid‐modified resin composite: F2000
Number of subjects: 18
Study 16827020 — intervention group
Group type: EXPERIMENTAL
Intervention: Base with a resin‐modified glass‐ionomer cement: Vitrebond
Number of subjects: 18
Study 16827020 — intervention group
Group type: COMPARATOR
Intervention: Control: no base
Number of subjects: 18
Study 12859559 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM intervention (allergen impermeable mattress covers and acaricidal washing detergent for bedding)
Number of subjects: 616
Study 12859559 — intervention group
Group type: COMPARATOR
Intervention: Control group (no special recommendations)
Number of subjects: 616
Study 10757257 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 8785393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramped hypertonic sodium dialysis (RHSD)
Number of subjects: 16
Study 8785393 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysis (SD)
Number of subjects: 16
Study 8785393 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term RHSD therapy
Number of subjects: 16
Study 1948517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime 250 mg IM
Number of subjects: 204
Study 1948517 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg IM
Number of subjects: 204
Study 6666222 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg ISDN sr
Number of subjects: 9
Study 6666222 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 9
Study 30659468 — intervention group
Group type: EXPERIMENTAL
Intervention: New standard operating procedure (SOP) using a combination of esketamine and propofol
Number of subjects: 0
Study 30659468 — intervention group
Group type: COMPARATOR
Intervention: Conscious sedation (CS) from the SIESTA trial
Number of subjects: 0
Study 30231074 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vehicle exposure to particulate metals (Al, Pb, Fe) during a highway commute
Number of subjects: 60
Study 30231074 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vehicle exposure to particulate metals (Al, Pb, Fe)
Number of subjects: 60
Study 28110894 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients (hs-CRP ≥3.84mg/L and Lp-PLA2 >239μg/L)
Number of subjects: 68
Study 28110894 — intervention group
Group type: COMPARATOR
Intervention: Low-to-intermediate-risk patients
Number of subjects: 68
Study 28110894 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients
Number of subjects: 68
Study 25898791 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPO with appositional screw fixation (group B)
Number of subjects: 60
Study 25898791 — intervention group
Group type: COMPARATOR
Intervention: MIPO without appositional screw fixation (group A)
Number of subjects: 60
Study 23283254 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 95
Study 23283254 — intervention group
Group type: COMPARATOR
Intervention: Topical ice pack
Number of subjects: 95
Study 23283254 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 95
Study 20817429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (ITD)
Number of subjects: 66
Study 20817429 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study 18292451 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled continuous interscalene block (PCISB)
Number of subjects: 87
Study 18292451 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled i.v. (opioid) analgesia (PCA)
Number of subjects: 87
Study 17088191 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anterior-posterior fusion
Number of subjects: 100
Study 17088191 — intervention group
Group type: COMPARATOR
Intervention: Posterior-only fusion
Number of subjects: 100
Study 12644417 — intervention group
Group type: EXPERIMENTAL
Intervention: English laryngoscope blade
Number of subjects: 300
Study 12644417 — intervention group
Group type: COMPARATOR
Intervention: Standard laryngoscope blade
Number of subjects: 300
Study 12644417 — intervention group
Group type: EXPERIMENTAL
Intervention: Both blades
Number of subjects: 300
Study 11021442 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite‐coated Freeman‐Samuelson (FS HA) total knee arthroplasty
Number of subjects: 51
Study 11021442 — intervention group
Group type: COMPARATOR
Intervention: Porous‐coated Miller‐Galante II (MG II) total knee arthroplasty
Number of subjects: 51
Study 9070551 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril 1 mg/day for 1 month and 2 mg/day for the following 2 months (n = 49)
Number of subjects: 100
Study 9070551 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 1 mg/day for 1 month and 2 mg/day for the following 2 months plus Verapamil 240 mg/day for 1 month and 360 mg/day for 2 months (n = 51)
Number of subjects: 100
Study 12959317 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (600 mg) in patients on phenobarbitone
Number of subjects: 16
Study 12959317 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (600 mg) in patients on sodium valproate
Number of subjects: 16
Study 12959317 — intervention group
Group type: COMPARATOR
Intervention: Oxcarbazepine (600 mg) in healthy control subjects
Number of subjects: 16
Study 3772833 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong buzzer condition
Number of subjects: 0
Study 3772833 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild buzzer condition
Number of subjects: 0
Study 3772833 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious and unstressful condition
Number of subjects: 0
Study 3772833 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong emotion
Number of subjects: 0
Study 31758920 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone (DRSP) 4 mg
Number of subjects: 24
Study 31758920 — intervention group
Group type: COMPARATOR
Intervention: Drospirenone (DRSP) 3 mg and Ethinyl Estradiol (EE) 0.02 mg
Number of subjects: 24
Study 29909977 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive Bare Metal Stent (RBMS)
Number of subjects: 66
Study 29909977 — intervention group
Group type: COMPARATOR
Intervention: Conventional Bare Metal Stent (CBMS)
Number of subjects: 66
Study 26493792 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH behavioural intervention (n=46)
Number of subjects: 90
Study 26493792 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control (n=44)
Number of subjects: 90
Study 24906459 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise dose for general health (8 kcal/kg body weight per week, about 900 kcal/wk)
Number of subjects: 198
Study 24906459 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise dose for weight loss (20 kcal/kg body weight per week, about 2,250 kcal/wk)
Number of subjects: 198
Study 24906459 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group receiving health information only
Number of subjects: 198
Study 24906459 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 198
Study 23770788 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (10 mg/kg body weight, 3 times before operation)
Number of subjects: 26
Study 23770788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 23770788 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 26
Study 23770788 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol and Placebo
Number of subjects: 26
Study 21364503 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg
Number of subjects: 100
Study 21364503 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 50 mg
Number of subjects: 100
Study 21364503 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg and Flurbiprofen axetil 50 mg (combination)
Number of subjects: 100
Study 21364503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study 18485028 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 70 mg/m² on day 1 (arm A)
Number of subjects: 95
Study 18485028 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 70 mg/m² on day 2 plus oral estramustine phosphate (EP) 840 mg total daily dose on days 1-5 (arm B)
Number of subjects: 95
Study 16455821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools received staff asthma-training session, advice on asthma policy, an emergency beta2-agonist inhaler with spacer, and whole-class asthma workshops.
Number of subjects: 193
Study 16455821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 193
Study 16455821 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 193
Study 16455821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention and Nonintervention groups
Number of subjects: 193
Study 14553956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (0.07 mg/kg once daily)
Number of subjects: 115
Study 14553956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 11061364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 20 mg/day
Number of subjects: 34
Study 11061364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8931406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 115
Study 8931406 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 115
Study 8931406 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior antibiotics
Number of subjects: 115
Study 1524682 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine rinse (Peridex)
Number of subjects: 94
Study 1524682 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 94
Study 2439798 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol (0.07 mg/kg i.v.)
Number of subjects: 16
Study 2439798 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol (0.2 mg/kg i.v.)
Number of subjects: 16
Study 2439798 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol (0.8 mg/kg i.v.)
Number of subjects: 16
Study 2439798 — intervention group
Group type: EXPERIMENTAL
Intervention: penbutolol (0.04 mg/kg i.v.)
Number of subjects: 16
Study 2439798 — intervention group
Group type: COMPARATOR
Intervention: propranolol (0.2 mg/kg i.v.)
Number of subjects: 16
Study 31306389 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume (HV) training group
Number of subjects: 65
Study 31306389 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume (LV) training group
Number of subjects: 65
Study 31306389 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 29462223 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone gel, 7.5%
Number of subjects: 4327
Study 29462223 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 4327
Study 27267154 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression-prevention, resilience promotion program
Number of subjects: 264
Study 27267154 — intervention group
Group type: COMPARATOR
Intervention: Advanced diabetes education program
Number of subjects: 264
Study 24313546 — intervention group
Group type: EXPERIMENTAL
Intervention: PPS-guided stress management programme
Number of subjects: 42